
IBM Stock: Stable Dividend or Stagnant Investment?
The AI race has heated up significantly but returns on…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Income Statement | ||||||
Revenue | -- | -- | -- | -- | -- | |
Gross Profit | -- | -- | -- | -- | -- | |
Operating Income | -$62.8M | -$61.1M | -$43.6M | -$15.4M | -$9.6M | |
EBITDA | -$62.1M | -$57.5M | -$39.1M | -$14.2M | -$8.5M | |
Diluted EPS | -$1.46 | -$1.38 | -$0.81 | -$0.35 | -$0.14 |
Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $107.4M | $132.8M | $82.9M | $84.8M | $81M | |
Total Assets | $108.8M | $133.8M | $85.8M | $87.1M | $82.7M | |
Current Liabilities | $5.9M | $5.8M | $6.5M | $8.1M | $5.3M | |
Total Liabilities | $6.6M | $6.4M | $8.6M | $58.6M | $58.7M | |
Total Equity | $102.2M | $127.4M | $77.2M | $28.5M | $24M | |
Total Debt | -- | -- | -- | -- | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$52M | -$49.5M | -$31.8M | -$12.2M | -$7M | |
Cash From Investing | -$25.1M | -$25.9M | $2.6M | -$10.9M | $6.5M | |
Cash From Financing | $3M | $48M | $32.1M | $305K | $74K | |
Free Cash Flow | -$52.1M | -$49.7M | -$31.8M | -$12.2M | -$7M |
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
In the current month, MIST has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MIST average analyst price target in the past 3 months is $10.25.
According to analysts, the consensus estimate is that Milestone Pharmaceuticals share price will rise to $10.25 per share over the next 12 months.
Analysts are divided on their view about Milestone Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Pharmaceuticals is a Sell and believe this share price will drop from its current level to $2.00.
The price target for Milestone Pharmaceuticals over the next 1-year time period is forecast to be $10.25 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
According to Wall Street analysts, the consensus rating for Milestone Pharmaceuticals is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
You can purchase shares of Milestone Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Pharmaceuticals shares.
Milestone Pharmaceuticals was last trading at $1.86 per share. This represents the most recent stock quote for Milestone Pharmaceuticals. Yesterday, Milestone Pharmaceuticals closed at $1.84 per share.
In order to purchase Milestone Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
The AI race has heated up significantly but returns on…
Trimble (NASDAQ:TRMB) is a hardware and software tech company that…
It seems like right now is a good time to…
Market Cap: $3.6T
P/E Ratio: 39x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.66% over the past day.
Pro-Dex [PDEX] is up 10.33% over the past day.
Samsara [IOT] is down 3.68% over the past day.